X0708 D LIVE 0001807983 Medicenna Therapeutics Corp. 2 BLOOR STREET W SUITE 903 TORONTO A6 ONTARIO, CANADA M4W 3E2 604-671-6673 CANADA (FEDERAL LEVEL) A2 Acquisition Corp. None Corporation true Fahar Merchant 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Executive Officer Director David Hyman 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Executive Officer Nageatte Ibrahim 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Executive Officer Rosemina Merchant 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Executive Officer Albert G. Beraldo 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Director John Geltosky 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Director Karim Lalji 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Director Richard Sutin 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Director Angelos Georgakis 2 Bloor Street W. Suite 903 Toronto A6 ONTARIO, CANADA M4W 3E2 Director Biotechnology Decline to Disclose 06b false 2026-05-28 true true true true true Each Unit is comprised of 1 common share and 1/2 of 1 common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of CDN$0.65 per Share for a period of 3 years following May 28, 2026. false 0 2343400 253458 2089942 The additional $2,089,942 may be received upon the exercise of common share purchase warrants if exercised in the U.S. U.S. dollar amounts based on the Bank of Canada average rate of exchange reported on May 28, 2026, which was CDN$1.3809 =US$1.00. false 3 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Medicenna Therapeutics Corp. /s/ David Hyman David Hyman Chief Financial Officer 2026-07-06